Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Disc Medicine, Inc. - Common Stock
(NQ:
IRON
)
43.48
+0.32 (+0.73%)
Streaming Delayed Price
Updated: 1:28 PM EDT, Aug 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Disc Medicine, Inc. - Common Stock
< Previous
1
2
Next >
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
June 09, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
May 11, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
April 21, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
April 13, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
March 31, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
March 21, 2023
IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Opco Inc (NASDAQ: IRON) Investor Notice: Investigation over Possible Securities Laws Violations
March 20, 2023
San Diego, CA -- (SBWIRE) -- 03/20/2023 -- An investigation was announced for investors of Disc Medicine Opco Inc (NASDAQ: IRON) shares over potential securities laws violations in connection with...
Via
SBWire
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
February 16, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
February 14, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
February 08, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
January 20, 2023
From
Disc Medicine Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.